EU Lawmakers Clash Over Role of Novel Nicotine Products in Tobacco Reform

EU legislators have returned from summer recess to continue deliberations on a comprehensive revision of the bloc’s tobacco laws, sparked by the European Commission’s April evaluation of the Tobacco Products Directive. The review highlights a decline in smoking but flags challenges from the rapid growth of novel nicotine products, prompting a split between those who argue the new rules should support these alternatives as smoking-cessation tools and those who view them as a health risk.

British American Tobacco disputes the evaluation’s evidence, while the World Vapers’ Alliance and Smoke Free Sweden claim it biases against harm-reduction. Scientific studies, including a Cochrane review and a Nature Reviews Cardiology paper, provide mixed findings on the relative safety of e-cigarettes and other products. With 94 million adult smokers and 30 million users of alternative nicotine products in Europe, the debate carries significant public-health and economic implications, influencing a sector that supports roughly 1.45 million jobs and €107 billion in tax revenue.